Evidence map›Paper›PMID 30118905›Full record

Trial reportPhotodiagnosis and photodynamic therapy2018

Photodynamic therapy for rosacea in Chinese patients.

Lili Fan, Rui Yin, Ting Lan, Michael R Hamblin

Abstract readClinical Trial
In one paragraph

Trial report in Photodiagnosis and photodynamic therapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
3.0field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it, 42 citations in OpenAlex.

  1. Pooled it
  2. Mechanisms and Recent Advances of Small-Molecule Therapeutics in Rosacea Treatment.Clinical, cosmetic and investigational dermatology · 2025
    Review
  3. Article
  4. Article
  5. Photodynamic Therapy: Past, Current, and Future.International journal of molecular sciences · 2024
    Review
  6. Article
  7. Review
  8. Effectiveness of VISIA system in evaluating the severity of rosacea.Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI) · 2022
    Article
  9. Effect and Safety of ALA-PDT Combined with 1550 nm Fractional Therapy Laser in Treating Rosacea.Evidence-based complementary and alternative medicine : eCAM · 2022
    Article
  10. Updates and Best Practices in the Management of Facial Erythema.Clinical, cosmetic and investigational dermatology · 2021
    Review
  11. Article
  12. Article
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Lili FanDepartment of Dermatology, Southwest Hospital, Army Medical University, Chongqing, 400038, China.
Rui YinDepartment of Dermatology, Southwest Hospital, Army Medical University, Chongqing, 400038, China. Electronic address: swyinrui@163.com.
Ting LanDepartment of Dermatology, Southwest Hospital, Army Medical University, Chongqing, 400038, China.
Michael R HamblinWellman Center for Photomedicine, Massachusetts General Hospital, Boston, MA, 02114, United States; Department of Dermatology, Harvard Medical School, Boston, MA 02115, United States; Harvard-MIT Division of Health Sciences and Technology, Cambridge, MA 02139, United States.
Army Medical University · CNHarvard University · US

Funding

Photodynamic Therapy of Localized InfectionsR01AI050875 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI HAMBLIN, MICHAEL R · 2003 to 2017
$4.8M
Synergistic Photodynamic Therapy for Catherer-Associated Urinary Tract InfectionsR21AI121700 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI HAMBLIN, MICHAEL R · 2016 to 2017
$462k
NIAID NIH HHS R01 AI050875NIAID NIH HHS R21 AI121700
6 · The paper itself

Abstract

backgroundRosacea is a common chronic cutaneous disorder which is characterized by flushing, erythema, papulopustules and telangiectasia. The pathogenesis of the disease is still unknown. A multifaceted approach is necessary to control the disease because of its tendency to relapse. New more effective treatment options are desirable to achieve a complete remission. Aminolevulinic acid-photodynamic therapy (ALA-PDT) is a well-established treatment for non-melanoma skin cancer and precancerous lesions. ALA- PDT can also be used for inflammatory disease, including acne vulgaris. However, little is known about the efficacy and safety of ALA-PDT for rosacea in Chinese patients with Fitzpatrick skin types III and IV.

objectivesTo investigate the efficacy and safety of ALA-PDT in the treatment of rosacea classified as erythematotelangiectatic type or papulopustular type.

methodsTwenty rosacea patients with either erythematotelangiectatic or papulopustular types were enrolled. 5% 5-Aminolevulinic acid in an oil-in-water emulsion was applied to the lesions under occlusion with plastic film for 2 h, and the lesions were irradiated with 100 mW/cm2, 80-90 J/cm2, LED red light (635 ± 15 nm) over 15 min in each session with four sessions at 10-day intervals. Objective measures (severity of flushing, erythema and telangiectasia, number of inflammatory lesions, VISIA Red Complexion Analysis images), subjective symptoms (including itching, prickling, burning, etc.) were recorded at baseline and at 4, 12 and 24 weeks after the last treatment. Adverse effects were recorded at each treatment and follow-up visit.

resultsDuring the follow-up period, all patients showed gradual objective clinical improvement compared with baseline (P < 0.01). Clinical inflammatory lesions disappeared completely in all patients after 24 weeks. Subjective symptoms, including flushing, itching, prickling, burning et al, had vanished and did not show any relapse during the follow-up period. The main side effects of ALA-PDT were pain, erythema, swelling and post- inflammatory hyperpigmentation. All side-effects were transient and tolerated by all the patients. No patients were dissatisfied with the therapeutic outcome.

conclusionsALA-PDT is an effective and safe approach for the treatment of rosacea of erythematotelangiectatic or papulopustular types, to control clinical manifestations and reduce subjective symptoms.

Indexed as

AdultAminolevulinic AcidAsian PeopleChinaEmulsionsFemaleHumansMaleMiddle AgedPhotochemotherapyPhotosensitizing AgentsProspective StudiesRosaceaYoung AdultAminolevulinic AcidEmulsionsPhotosensitizing Agents5-aminolevulinic acidChinese skin typesErythemato-telangiectatic or papulopustular typesPhotodynamic therapyRed light emitting diodesrosacea

Identifiers

PMID30118905
PMCPMC6289730
OpenAlexW2887295860

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.